BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Amyotrophic Lateral Sclerosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Amyotrophic Lateral S
 clerosis\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07294144-10800@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Qalsody (Tofersen): Phase 2 readout est. (NCT07294144)
DESCRIPTION:Qalsody (Tofersen)\, phase 2\, Amyotrophic Lateral Sclerosis.\n
 Study: Tofersen in Non-SOD1 ALS\nEstimated primary completion: January 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07294144
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04057898-8762@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ibudilast: Phase 2/3 readout est. (NCT04057898)
DESCRIPTION:Ibudilast\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: 
 Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label E
 xtension for 6 Months in Patients With ALS\nEstimated primary completion: 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ibudilast
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT040
 57898
URL:https://assetmemo.bio/drug/ibudilast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07688239-6849@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Foralumab: Phase 2 readout est. (NCT07688239)
DESCRIPTION:Foralumab\, phase 2\, Amyotrophic Lateral Sclerosis.\nStudy: Th
 e BANYAN Trial\, an ALS MyMatch Trial Evaluating Safety\, Biomarker Activi
 ty\, and Microglial Activation of Nasal Foralumab\nEstimated primary compl
 etion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/for
 alumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07688239
URL:https://assetmemo.bio/drug/foralumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04856982-10800@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270807
DTEND;VALUE=DATE:20270808
SUMMARY:Qalsody (Tofersen): Phase 3 readout est. (NCT04856982)
DESCRIPTION:Qalsody (Tofersen)\, phase 3\, Amyotrophic Lateral Sclerosis.\n
 Study: Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and Abo
 ut Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Develop
 ed ALS Symptoms\nEstimated primary completion: 7 August 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/tofersen#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04856982
URL:https://assetmemo.bio/drug/tofersen#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082192-8958@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:CB03-154: Phase 2/3 readout est. (NCT07082192)
DESCRIPTION:CB03-154\, phase 2/3\, Amyotrophic Lateral Sclerosis.\nStudy: A
  Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 
 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)\nEstimated prim
 ary completion: 30 September 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/cb03-154#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07082192
URL:https://assetmemo.bio/drug/cb03-154#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03127267-787@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Masitinib: Phase 3 readout est. (NCT03127267)
DESCRIPTION:Masitinib\, phase 3\, Amyotrophic Lateral Sclerosis.\nStudy: Ef
 ficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Pati
 ents\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/masitinib#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03127267
URL:https://assetmemo.bio/drug/masitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325591-789@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tazbentetol (SPG302): Phase 2/3 readout est. (NCT07325591)
DESCRIPTION:Tazbentetol (SPG302)\, phase 2/3\, Amyotrophic Lateral Sclerosi
 s.\nStudy: Efficacy and Safety of Tazbentetol in ALS Participants\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tazbentetol-spg302#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07325591
URL:https://assetmemo.bio/drug/tazbentetol-spg302#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07174492-787@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Masitinib: Phase 3 readout est. (NCT07174492)
DESCRIPTION:Masitinib\, phase 3\, Amyotrophic Lateral Sclerosis.\nStudy: Ef
 ficacy and Safety of Masitinib in Combination With SoC Versus Placebo in t
 he Treatment of ALS Patients\nEstimated primary completion: 31 December 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/masitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07174492
URL:https://assetmemo.bio/drug/masitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351592-7568@assetmemo.bio
DTSTAMP:20261121T005659Z
DTSTART;VALUE=DATE:20320321
DTEND;VALUE=DATE:20320322
SUMMARY:ALN-SOD: Phase 1/2 readout est. (NCT06351592)
DESCRIPTION:ALN-SOD\, phase 1/2\, Amyotrophic Lateral Sclerosis.\nStudy: Fi
 rst in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic
  Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)\nE
 stimated primary completion: 21 March 2032. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/aln-sod#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06351592
URL:https://assetmemo.bio/drug/aln-sod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
